TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative death or MI rates
Endpoint domain: Mortality/survival
Primary endpoint: Mental health quality improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wheal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Limits of stability (LOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural stability (PST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA repair capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work productivity score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean bowel movements per day after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean stool volume after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete response (stool volume < 250 ml/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nasal Hyperreactivity (NHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-hexosaminidase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eosinophilic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bleeding amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of the implant for maintenance of IGF‐I and GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endoscopic scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal atrophy reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's BMI z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of follow-up INRs within the therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bradykinin-mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: t-PA release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hilar dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative levels of alanine transaminase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of surgical material
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bond failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clinically relevant pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: statistically relevant pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of ex vivo colorectal tissue HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brand appeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Susceptibility to smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of resolution of cellulitis or erysipelas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative uncorrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Subtherapeutic INR development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Supra-therapeutic INR results leading to warfarin dosing interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Negative rates of HCV-RNA in PBMC and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basal and insulin stimulated PDH activities normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indexes of poor insulin sensitivity (FG, FI, FIRI, G-AUC, I-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of antihypertensive medications while maintaining controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to the first Clinically Significant Upper and/or Lower GI Event
Endpoint domain: Mortality/survival
Primary endpoint: time to stable response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of sustained early response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eating psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC score at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand grip dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM score at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) at 3 and 6 months post hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of at least two points on the symptom intensity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of symptoms (abdominal fullness, bloating, sensation of slow digestion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with moderate or severe global complaints
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effectiveness of magnesium sulfate as an antiarrhythmic agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CP (Cuff Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response during alcohol session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of disgust
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Willingness to repeat same regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recognition of psychological needs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of borderline/clinical depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: trans-lycopene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total-cis-lycopene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean arterial pressure (MAP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic arterial pressure (DAP) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (Asthma Quality of Life Questionnaire score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 7-year disease-specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 7-year overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean Central Macular Thickness (CMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstructive urinary symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeling a bulge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Syndecan-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of patient-months on TB treatment where at least 20% of doses were missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between test environments for ABA-2 subtests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with telerehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reliability of telerehabilitation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of connective tissue edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quicker wound healing process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Avoidance of operative stress (escharotomy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of GA area covered by the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Variability (HRV) stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the curve (AUC) for model performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pharyngocutaneous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RFLI score mean difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cognitive impairments
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average time of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: subclinical cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVEF decline per 100 mg/m2 of doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Likelihood of achieving HbA1c <53 mmol/mol (<7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative IF depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic eye shell maintenance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acetone buildup levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lesion amelioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total mean number of deaths and injuries
Endpoint domain: Mortality/survival
Primary endpoint: Mean cost for a household
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lipid profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first recurrence of sustained PAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in total daily insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ASAS20/ASAS40 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean left ventricular mass difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amount of withdrawal relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective and objective nicotine delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in T-ADP levels after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resistin levels after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HMW:T-ADP ratio after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of wheezing at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of ischaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fibrinolytic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sexual/Relationship Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinicians' ability to implement TSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge test gains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean decrease in maximum urethral pressure (MUP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: International Prostate Symptom Score Quality of Life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inhaler actuation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: binge eating scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area swept during activities of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of orthostatic hypotension after standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole mouth MPI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gingival margin MPI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interproximal MPI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct post-class car seat installation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faster onset of insulin action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shorter duration of insulin action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soluble E-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in telangiectasia density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of intra-amniotic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in overall health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5S score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum total testosterone concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration‐time curve through 24 hours (AUC[0‐24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration‐time curve through 72 hours (AUC[0‐72])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FAAH1 activity inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatty acid amide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of PF‐04457845
Endpoint domain: Adverse events/effects
Primary endpoint: distance walked in six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative RBC transfusion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative phlebotomy loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cure rate of neonatal conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to pay for autologous blood donation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median length of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: need for blood transfusion during operation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of volunteers with SBA titres ≥1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnosis of disruptive behavior or anxiety disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stroop Colour-Word Interference test change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative for delirium on the CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of sites with periodontal probing depth >/=6.0mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: independence in walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: dependency in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hospitalization status
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: SOCS1 mRNA expression in fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: cure rates of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: application site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Heart-mediastinum ratio for MIBG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete remission of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor clinical outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in wall motion score index from rest to peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete defect coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔFEV1 greater than or equal to 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean improvement in peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean improvement in percent-expected peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: coronary atherosclerotic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: glycemic status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of neutrophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil elastase in sputum supernatant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 5-year MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline to week 8 in the YGTSS-TTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Tourette's Syndrome improvement score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative incidence of vomiting at 24 h
Endpoint domain: Adverse events/effects
Primary endpoint: EGF excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sBP and dBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of AF triggered by Iso vs Ado
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS score for pain/discomfort after 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with inflamed skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean diastolic blood pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Protection from STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: No signs or symptoms of cardiovascular distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence of heart failure
Endpoint domain: Mortality/survival